News articles about Ocular Therapeutix (NASDAQ:OCUL) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ocular Therapeutix earned a news impact score of 0.19 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.7078727572187 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Ocular Therapeutix (OCUL) Downgraded by Zacks Investment Research to “Sell” (americanbankingnews.com)
- Is There Now An Opportunity In Ocular Therapeutix Inc (NASDAQ:OCUL)? (finance.yahoo.com)
- Investor’s Roundup (ATR in Focus) – Ocular Therapeutix (NASDAQ:OCUL) (thestockgem.com)
- ValuEngine Upgrades Ocular Therapeutix (OCUL) to Sell (americanbankingnews.com)
Several brokerages recently weighed in on OCUL. Zacks Investment Research upgraded shares of Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research report on Tuesday, March 13th. Cantor Fitzgerald reiterated a “buy” rating and issued a $22.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, March 8th. BTIG Research upgraded shares of Ocular Therapeutix from a “neutral” rating to a “buy” rating in a research report on Friday, January 19th. ValuEngine downgraded shares of Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, BidaskClub upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Tuesday, March 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $11.70.
Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.14. Ocular Therapeutix had a negative net margin of 3,296.20% and a negative return on equity of 145.73%. The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.51 million. During the same period in the previous year, the firm earned ($0.52) EPS. Ocular Therapeutix’s revenue was up .0% on a year-over-year basis. equities research analysts predict that Ocular Therapeutix will post -1.91 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/04/06/ocular-therapeutix-ocul-receiving-somewhat-positive-press-coverage-report-shows/2029289.html.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.